The MHRA approved the Wegovy pill on 11 June 2026, the first GLP-1 weight-loss tablet in the UK. It produced an average weight loss of 13.6% in trials.

Apitegromab reduced muscle loss on Mounjaro by about 55%, but not strength. Most people can protect muscle with protein and exercise instead.

Most weight lost on Wegovy and Mounjaro is fat, not muscle. New scans show around 84% is fat, plus how to keep your muscle while losing weight.

Retatrutide, a triple-hormone injection, produced up to 30.3% average weight loss in the phase 3 TRIUMPH-1 trial. Not yet approved in the UK.

New research finds GLP-1 users are judged more harshly than dieters, and sometimes more than people who haven't lost weight. Here's what the study shows.

Phase 3 trial: survodutide produced up to 16.6% weight loss in 76 weeks. How it compares to Mounjaro, Wegovy, and Wegovy 7.2 mg.

A new MRI study of 615 adults found higher ultra-processed food intake was linked to more fat stored inside muscle tissue, even when calories were matched.

A Nature study of 27,885 people identified gene variants that predict GLP-1 weight loss and nausea risk, including one specific to Mounjaro users.

The FDA has approved Foundayo (orforglipron), a daily GLP-1 pill for weight loss with no fasting requirements. Average weight loss of 11.2% at 72 weeks.

The OASIS 4 trial found oral semaglutide 25 mg produced 13.6% weight loss over 64 weeks, comparable to injectable Wegovy. UK approval expected late 2026.